The Cytotoxic Effect of Sunitinib on Human Bronchial Carcinoid Cell Lines and Primary Cultures is Counteracted by EGF and IGF-1, but not by VEGF

#933

Introduction: Bronchial carcinoids (BC) are rare tumors originating from endocrine cells dispersed in the respiratory epithelium. The main BC treatment is surgery, but which is not feasible for large, infiltrating and metastatic disease. In these settings, medical therapy is often tried. Therefore it is important to identify new therapeutic targets and new molecules capable of providing adequate medical treatment for patients with BC. Sunitinib is an oral, small-molecule, multi-targeted receptor tyrosine kinase inhibitor.

Aim(s): To verify if Sunitinib is active in inhibiting human cell viability and what are its targets in these cells.

Materials and methods: Human BC cell lines (NCH-727, NCI-H727 cells) and human BC primary cultures were treated with Sunitinib 5 µM and/or EGF 30 nM, IGF1 50 nM, or VEGF 10 nM. Cell viability and caspase 3/7 activation were measured after 48 h of treatment.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Gagliano T, Gennari G, Tassinari M, Bellio M, Molè D,

Keywords: BC, RTK, Sunitinib,